Clinical trials are special research studies designed to test promising new medical treatments. The research being conducted may be evaluating new methods for cancer prevention, new diagnostic procedures, or new treatments. Clinical trials also test new ways of using existing treatments for cancer. Clinical trials are often sought out by melanoma patients when the few traditional treatments that are available aren't working for them.
As clinical trials prove new treatments to be safe and effective, these new treatments join the others as standards of care. The treatments for cancer that are now highly respected as standards of cancer care were previously proven effective by similar clinical trials.
Clinical trials involving new cancer therapies progress through a series of steps called phases. Having these separate phases allows researchers to learn more about the safety and effectiveness of the new therapy or drug in a progressively more specific way while also safeguarding the safety of the patients involved in the study.
This is the first testing of a new drug or therapy on humans. Usually enrolling only a small number of participants, phase I trials are seeking answers to these types of questions:
Most often the highest dose with acceptable levels of side effects will be sent forward for Phase II testing.
This phase of testing usually focuses on treating one specific type of cancer and involves fewer than 100 patient participants. Phase II trials are where the effectiveness of the new drug or therapy against a particular type of cancer is evaluated. Researchers evaluate how the new treatment affects the body as a whole as well as testing the treatment's effectiveness in eradicating specific cancer cells.
In phase III trials, researchers compare the safety and effectiveness of the new drug or therapy against the safety and effectiveness of current standard therapy. These studies can include hundreds of patient participants at different treatment centers across the country. Patients who qualify for these studies are placed randomly into either the new treatment group or the standard treatment group to prevent bias from affecting the integrity of the outcome.
Each clinical trial has its own protocol. The protocol states:
Having very specific eligibility criteria ensures that the new drug or therapy is tested on a group of people who all have the same characteristics and who can all benefit the most from a favorable outcome of the study. These criteria also help to make sure that the findings of the study reflect the actual effects of the new drug or therapy and that no outside circumstances changed the outcome. Eligibility Criteria usually include:
Cancer Shock: Your Feelings Matter
Source:
National Cancer Institute